2-(2-bromobenzyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid 4-fluorobenzylamide | 1556810-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(2-bromobenzyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid 4-fluorobenzylamide
• 英文别名: 2-(2-Bromo-benzyl)-5-hydroxy-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid 4-fluoro-benzylamide；2-[(2-bromophenyl)methyl]-N-[(4-fluorophenyl)methyl]-5-hydroxy-6-oxo-1H-pyrimidine-4-carboxamide
• CAS: 1556810-25-3
• 化学式: C₁₉H₁₅BrFN₃O₃
• 分子量: 432.249
• InChiKey: LFCNLXNJPPZOPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  90.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(2-bromobenzyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid methyl ester 、 对氟苄胺 以This gave the title compound as a white solid (0.072 g; 70%)的产率得到2-(2-bromobenzyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid 4-fluorobenzylamide
  参考文献：
  名称：

  Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

  摘要：

  本发明涉及具有一般式（Di）、（Dii）或（Diii）的化合物，可选地以药学上可接受的盐、溶剂化物、多晶形、共药、共晶体、前药、互变异构体、外消旋体、对映体或其混合物的形式存在，其在治疗、改善或预防病毒性疾病方面具有用途。此外，还公开了具体的组合疗法。

  公开号：

  US08921388B2

文献信息

• DIHYDROXYPYRIMIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：Savira Pharmaceuticals GmbH

  公开号：EP2885289A1

  公开（公告）日：2015-06-24
• US8921388B2
  申请人：——

  公开号：US8921388B2

  公开（公告）日：2014-12-30
• [EN] DIHYDROXYPYRIMIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS D'ACIDE DIHYDROXYPYRIMIDINECARBONIQUE ET LEUR UTILISATION DANS LE TRAITEMENT, L'AMÉLIORATION OU LA PRÉVENTION D'UNE MALADIE VIRALE
  申请人：SAVIRA PHARMACEUTICALS GMBH

  公开号：WO2014023691A1

  公开（公告）日：2014-02-13

  The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, formula (Di), (Dii), (Diii) which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.